Inhibitors in haemophilia B: The Italian experience

Haemophilia

Volumn 19, Issue 5, 2013, Pages 686-690

  Castaman, G ^a   Bonetti, E ^b   Messina, M ^c   Morfini, M ^d   Rocino, A ^e   Scaraggi, F A ^f   Tagariello, G ^g  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e San Giovanni Bosco Hospital   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g Transfusion and Hemophilia Center ^*  (Italy)

Author keywords

Anaphylaxis; Factor IX; Hemophilia B; Inherited bleeding disorders; Inhibitor

Indexed keywords

ADRENALIN; BLOOD CLOTTING FACTOR 9 CONCENTRATE; FRESH FROZEN PLASMA; HYDROCORTISONE; INFUSION FLUID; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COUGHING; CYANOSIS; DRUG HYPERSENSITIVITY; EDEMA; GENE DELETION; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; LABIAL EDEMA; MALE; NEPHROTIC SYNDROME; NONSENSE MUTATION; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY DISTRESS; SCHOOL CHILD; TACHYCARDIA; TONGUE EDEMA; TREATMENT RESPONSE;

ANAPHYLAXIS; FACTOR IX; HEMOPHILIA B; INHERITED BLEEDING DISORDERS; INHIBITOR;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; FACTOR IX; FEMALE; HEMOPHILIA B; HUMANS; INFANT; ITALY; MALE; PREVALENCE;

EID: 84883054169     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12158     Document Type: Article

References (17)

1. Giangrande P. Haemophilia B: christmas disease. Expert Opin Pharmacother 2005; 6: 1517-24.
2. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophilias. Lancet 1992; 339: 594-8.
3. Sultan Y, the French hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-2.
4. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia 1996; 2: 28-31.
5. Warrier I, Ewenstein B, Koerper MA et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
6. Ewenstein BM, Takemoto C, Warrier I et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-6.
7. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency: a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15: 1027-31.
8. Iorio A, Oliovecchio E, Morfini M, Mannucci PM, Association of Italian Hemophilia Centres Directors. Italian registry of haemophilia and allied disorders. objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
9. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
10. Gringeri A, Mannucci PM, for the Italian Association of Haemophilia Centres. Italian guidelines for diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-19.
11. Hassan HJ, Leonardi A, Guerriero R et al. Hemophilia B with inhibitor: molecular analysis of the subtotal deletion of the factor IX gene. Blood 1985; 66: 728-30.
12. Belvini D, Salviato R, Radossi P et al., the AICE HB study group. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 2005; 90: 635-42.
13. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factor VIII and IX. Haemophilia 2006; 12(Suppl 6): 15-23.
14. Dimichele D. The North American immune tolerance registry: contribution to the thirty-year experience with immune tolerance registry. Haemophilia 2009; 15: 320-8.
15. Dimichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-15.
16. Warrier I Inhibitors in haemophilia B. In: Lee C, Berntorp E, Hoots KW eds. Textbook of Hemophilia, (1st edn). Oxford, UK: Blackwell Publishing Ltd, 2005, 97-100.
17. Thorland EC, Drost JB, Lusher JM et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5: 101-5.